New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell LymphomaByAmi Ali, PharmD, BCOP,Mary Dzhuryan, PharmD Candidate,Mehrnaz Razavi Vakhshoori, PharmD CandidateJune 27th 2025The FDA approved acalabrutinib as a frontline option for untreated mantle cell lymphoma.